About bicara therapeutics inc. - BCAX
Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and it developing first-in-class biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company’s bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, is a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.
BCAX At a Glance
Bicara Therapeutics, Inc.
116 Huntington Avenue
Boston, Massachusetts 02116
| Phone | 1-617-468-4219 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -51,985,000.00 | |
| Sector | Health Technology | Employees | N/A | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
BCAX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | N/A |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
BCAX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
BCAX Liquidity
| Current Ratio | 15.318 |
| Quick Ratio | 15.318 |
| Cash Ratio | 15.276 |
BCAX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -43.198 |
| Return on Equity | -51.667 |
| Return on Total Capital | -23.72 |
| Return on Invested Capital | -51.572 |
BCAX Capital Structure
| Total Debt to Total Equity | 0.301 |
| Total Debt to Total Capital | 0.30 |
| Total Debt to Total Assets | 0.281 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 0.17 |